Navigation Links
PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
Date:8/25/2008

onomic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, Perceptive Informatics is a trademark of Perceptive Informatics, Inc., and ClinPhone is a registered trademark of ClinPhone Limited. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Senior Director of Public Relations Rebecca Passo

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel : +617-681-1817

Jennifer.Baird@PAREXEL.com rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... DUBLIN , May 20, 2015 Research ... announced the addition of the "2015 Global ... to their offering. The primary goal ... of flow cytometry instruments and reagents. Key information ... drive the selection of flow cytometers, predominantly used ...
(Date:5/21/2015)... May 21, 2015 Veolia’s environmental ... exclusive North American distribution agreement with VWR to ... , With more than 160 years of experience, ... services for laboratory and production facilities, has cultivated ... and differentiated services to enable science. Endetec’s ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... LLC.,today announced the addition of Mark Scherling to ... FCP as Program,Management Office and Siemens Practice Director., ... thought leadership,experience to FCP. Prior to joining FCP, ... at Catholic Healthcare West. Prior to that,responsibility, Mark ...
... Technologies GmbH,the leading developer of RAFT intervention therapeutics, ... trial of its lead RAFT modulator,TF002 in patients ... miltefosine, exerts its anti- inflammatory activity via RAFT,modulation. ... cells that,play a role in the complex physiological ...
... February 15, 2008 USC and Second Sight Medical Products ... announced today that they have completed enrollment of the first ... Argus II Retinal Prosthesis System. They also announced that enrollment ... Mexico. , We are pleased that Second Sight, along ...
Cached Biology Technology:FCP Welcomes Mark Scherling 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 3USC and second sight announce European clinical trial for Argus II retinal implant 2USC and second sight announce European clinical trial for Argus II retinal implant 3
(Date:5/14/2015)... DUBLIN , May 14, 2015 Research and ... addition of the "Fingerprint Sensors Market in Smart ... This report believes that 2014 was a watershed ... to Apple,s introduction of ,Apple Pay,. Apple gave fingerprint ... its mobile payment service. Fingerprint sensors are a must-have ...
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Fla. For years, pilots flying into combat have jammed ... turns out that moths can do it, too. A ... hawkmoths use sonic pulses from their genitals to respond to ... to jam the echolocation ability of their predators. ...
... the VTT Technical Research Centre of Finland, lignocellulosic biomass can ... price of less than one euro per litre. A new ... half the energy of wood raw materials to the end-product. ... commercial-scale production plant in Europe. VTT has assessed the ...
... 2000, researchers at the UCLA Center for Sleep Research ... disorder characterized by uncontrollable periods of deep sleep, had ... their brains than healthy people. The study was the ... disorder. Subsequent work by this group ...
Cached Biology News:UF researcher shows hawkmoths use ultrasound to combat bats 2UF researcher shows hawkmoths use ultrasound to combat bats 3Gasification method turns forest residues to biofuel with less than a euro per liter 2UCLA researchers find new clue to cause of human narcolepsy 2
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: